Financial Survey: Nantkwest (NASDAQ:NK) & Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) and Nantkwest (NASDAQ:NK) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Volatility and Risk

Dyadic International has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Nantkwest has a beta of 3.05, suggesting that its share price is 205% more volatile than the S&P 500.

Insider and Institutional Ownership

12.9% of Dyadic International shares are held by institutional investors. Comparatively, 6.2% of Nantkwest shares are held by institutional investors. 24.8% of Dyadic International shares are held by company insiders. Comparatively, 72.1% of Nantkwest shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Dyadic International and Nantkwest’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dyadic International $1.68 million 144.21 -$8.31 million ($0.31) -28.45
Nantkwest $40,000.00 26,646.68 -$65.79 million ($0.70) -15.46

Dyadic International has higher revenue and earnings than Nantkwest. Dyadic International is trading at a lower price-to-earnings ratio than Nantkwest, indicating that it is currently the more affordable of the two stocks.


This table compares Dyadic International and Nantkwest’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dyadic International -523.65% -22.87% -22.05%
Nantkwest -112,350.85% -51.94% -43.75%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Dyadic International and Nantkwest, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyadic International 0 0 2 0 3.00
Nantkwest 0 0 0 0 N/A

Dyadic International currently has a consensus target price of $12.50, indicating a potential upside of 41.72%. Given Dyadic International’s higher possible upside, equities research analysts clearly believe Dyadic International is more favorable than Nantkwest.


Dyadic International beats Nantkwest on 9 of the 13 factors compared between the two stocks.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.

About Nantkwest

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with's FREE daily email newsletter.